Treatment interruption in chronic HIV-1 infection: does it deliver?

被引：1
|
作者：
Willberg, Christian B. [1 ]
Nixon, Douglas F. [1 ]
机构：
[1] UCSF, Div Expt Med, San Francisco, CA 94110 USA
来源：
CURRENT OPINION IN HIV AND AIDS | 2007年 / 2卷 / 01期
关键词：
chronic infection; highly active antiretroviral therapy; HIV-1; treatment interruption;
D O I：
10.1097/COH.0b013e3280119307
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Purpose of review This review sets out to overview treatment interruption in chronic HIV-1 infection: what treatment interruption promised, results from recent trials, and what the future holds. Recent findings Recent studies have produced mixed results; several trials have been prematurely halted, whereas others have reported more positive outcomes. One consistent finding has been the identification of the CD4 T-cell count nadir as a critical parameter in determining the outcome of treatment interruption. Summary The use of treatment interruption is still controversial, but it is becoming clear that certain individuals could benefit, and partial treatment interruption strategies warrant further investigation.
引用
收藏
页码：26 / 30
页数：5
相关论文
共 50 条
  • [31] Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection
    Burton, CT
    Nelson, MR
    Hay, P
    Gazzard, BG
    Gotch, FM
    Imami, N
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 142 (02): : 354 - 361
  • [32] Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection
    Rinaldi, Francesca
    Rolla, Serena
    Galli, Laura
    Poli, Andrea
    Muccini, Camilla
    Mastrangelo, Andrea
    Tavano, Cinzia
    Lazzarin, Adriano
    Bartoloni, Alessandro
    Castagna, Antonella
    NEW MICROBIOLOGICA, 2020, 43 (02): : 55 - 57
  • [33] The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
    García, F
    Plana, M
    Ortiz, GM
    Bonhoeffer, S
    Soriano, A
    Vidal, C
    Cruceta, A
    Arnedo, M
    Gil, C
    Pantaleo, G
    Pumarola, T
    Gallart, T
    Nixon, DF
    Miró, JM
    Gatell, JM
    AIDS, 2001, 15 (09) : F29 - F40
  • [34] HIV-1 protease does not play a critical role in the early stages of HIV-1 infection
    Uchida, H
    Maeda, Y
    Mitsuya, H
    ANTIVIRAL RESEARCH, 1997, 36 (02) : 107 - 113
  • [35] Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency
    Gornalusse, German Gustavo
    Vojtech, Lucia N.
    Levy, Claire N.
    Hughes, Sean M.
    Kim, Yeseul
    Valdez, Rogelio
    Pandey, Urvashi
    Ochsenbauer, Christina
    Astronomo, Rena
    McElrath, Julie
    Hladik, Florian
    VIRUSES-BASEL, 2021, 13 (08):
  • [36] Changes in CD4+ T-Cell Differentiation Phenotype During Structured Treatment Interruption in Patients With Chronic HIV-1 Infection
    Alexander, Thomas H.
    Ortiz, Gabriel M.
    Wellons, Melissa F.
    Allen, Andrew
    Grace, Edward J., II
    Schweighardt, Becky
    Brancato, Jason
    Sandberg, Johan K.
    Furlan, Scott N.
    Miralles, G. Diego
    Nixon, Douglas F.
    Bartlett, John A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (05) : 475 - 481
  • [37] Treatment interruption as a tool to measure changes in immunologic response to HIV-1
    Kutzler, Michele A.
    Jacobson, Jeffrey M.
    CURRENT OPINION IN HIV AND AIDS, 2008, 3 (02) : 131 - 135
  • [38] Evaluating lncRNA Expression Patterns during HIV-1 Treatment Interruption
    Schynkel, Tinus
    van Snippenberg, Willem
    Van Hecke, Clarissa
    Vandekerckhove, Linos
    Trypsteen, Wim
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [39] Does HIV-2 protect against HIV-1 infection?
    Aaby, P
    Poulsen, AG
    Larsen, O
    Christiansen, CB
    Jensen, H
    Melbye, M
    Naucler, A
    Dias, F
    AIDS, 1997, 11 (07) : 939 - 940
  • [40] GLUCOSIDASE INHIBITORS FOR TREATMENT OF HIV-1 INFECTION
    RATNER, L
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) : 165 - 173
12345